-
CSE professor’s machine learning start-up, GraphLab, scores $6.75M in venture funding, joins C4C incubator
GraphLab Inc., a start-up company founded by UW professor Carlos Guestrin, announced this week a $6.75 million Series A funding led by Madrona Venture Group and NEA. The company will be taking up residence in the C4C New Ventures Facility, UW’s start-up incubator on campus. Guestrin, who is also the company’s CEO, began the GraphLab open source project five years ago, GraphLab Inc is building… View More
-
UW spin-out LumiSands has a bright idea for powering LEDs
Chang-Ching Tu was not necessarily looking to start a business when he first contacted the UW Center for Commercialization (C4C). He wanted to continue research on his invention— a cheaper and more eco-friendly material that replaces an important component of LED lights. Working with Dr. Lih Y. Lin, UW professor of electrical engineering, Tu had discovered that silicon phosphors hold promise for replacing the rare… View More
-
White House Selects UW Spin-out Greenroads As A “Champion of Change” For Its Contribution to Sustainable Transportation
UW spin-out company Greenroads was honored on Wednesday, March 8, 2013 as a White House Champion of Change for Transportation Technology Solutions in recognition for its unique ratings system designed to certify sustainable roadway and transportation projects. The Champions of Change program was created as an opportunity for the White house to feature groups of Americans – individuals, businesses and organizations – who are doing… View More
-
UW Spin-out NanoFacture Gives Researchers a Low-Cost Alternative to Purifying DNA Samples; Targets $3 Billion Device Market
More than 45,000 research laboratories worldwide, and 8,000 in the US alone, conduct research that requires DNA separation and purification, driving a $3 billion global market for sample preparation devices and disposables in 2013. The median recurring annual sample preparation budget for reagents and kits is $5K to $10K per lab. NanoFacture, a new UW spin-out, is bringing to market a technology that addresses the… View More
-
BEAT BioTherapeutics Corporation closes $2.5MM Seed Financing to develop its gene therapy treatment for heart failure
University of Washington spin-out aims to refuel pumping power of the heart BEATBio, a Seattle-based biotechnology company focused on the development of a novel gene therapy to improve cardiac performance in the setting of heart failure, today announced the closing of a $2.5 million seed stage investment with funding provided by CET Capital Partners. Participating investors include the W Fund. The proceeds will be used… View More
-
UW start-up EnVitrum turns trash glass into bricks; wins Phase II NSF SBIR of $500K to scale production
UW start-up EnVitrum has been awarded a phase II NSF SBIR of $500k for two years to perform development related to scaling up their environmentally friendly process for making ceramic products from waste glass. UW graduate students Grant Marchelli and Renuka Prabhakar paired up in a Mechanical Engineering lab about three years ago to pursue a shared interest in environmental sustainability. They decided to make… View More
-
Start-up company Lamprogen to join C4C Incubator
UW biomedical spin-out Lamprogen, founded by UW Professor of Chemistry Daniel Chiu, has joined the C4C New Ventures Facility (NVF). The NVF at Fluke Hall is a business incubator that provides dedicated space and facilities for translational research and for early-stage business development of technologies en route to commercialization. Lamprogen’s mission is to bring new products to market that address the needs of the biomedical… View More
-
Japanese drugmaker Takeda secures rights to lupus drugs from UW spinout Resolve Therapeutics in $255M deal
Takeda Pharmaceutical Company and Resolve Therapeutics today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus and other autoimmune diseases. The lead compound, RSLV-132, a novel nuclease protein, will begin clinical development later this year. Resolve Therapeutics is a spinout of the University of Washington, where it was developed in the labs of rheumatologist Keith Elkon and… View More
-
UW Professor Jim Olson’s start-up company Blaze Bioscience Raises $8.5M to help surgeons pinpoint cancer with “tumor paint”
Seattle biotechnology start-up Blaze Bioscience has raised $8.5 million to continue developing technologies that are designed to help surgeons more easily identify cancer cells in the body. Total funding in the company now stands at $9.8 million. Blaze said that the money came from individual investors, including doctors and biotech execs. Blaze’s Tumor Paint technology is designed to provide real-time, high-resolution visualization of cancer cells,… View More
-
Stillaguamish Tribe to Invest $5 Million in UW Spin-out MicroGREEN Polymers
MicroGREEN Polymers, Inc. announced that the Stillaguamish Tribe of Indians has made a strategic investment of $5 million in MicroGREEN. This round of funding, the first closing in a $20 million round, will enable MicroGREEN to expand its commercial production capabilities to produce a wide range of environmentally responsible cups and trays for consumer use. The Stillaguamish Tribe will also use MicroGREEN’s cups in their… View More
Follow Us On Twitter
Join Our Mailing List